Safety, Toxicity, and Regulatory Aspects of Herbal Medicines

Dr. Lukas Andreas Keller [1*], Dr. Sofia Elena Meier [2], Dr. Fabian Marcel Rossi-Meier [3]
[1] PhD, Department of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland
[2] PhD, School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland
[3] PhD, Swiss Nanoscience Institute, University of Basel, Basel, Switzerland

* Corresponding Author: **Dr. Lukas Andreas Keller**

Article Info

ISSN (online): 3107-393X
Volume: 01
Issue: 03
May-June 2024
Received: 10-03-2024
Accepted: 12-04-2024
Published: 14-05-2024
Page No: 57-66

Abstract
Herbal medicines have been utilized for centuries across diverse cultures and continue to represent a significant component of global healthcare systems, with the World Health Organization estimating that approximately 80% of the population in developing countries relies on traditional herbal remedies for primary healthcare needs. Despite their widespread acceptance and perceived natural safety, herbal medicines are not without risks, as adverse effects, herb-drug interactions, contamination with heavy metals and pesticides, adulteration with synthetic pharmaceuticals, and intrinsic toxicity pose substantial safety concerns. This article aims to provide a comprehensive review of the safety, toxicity, and regulatory aspects governing herbal medicines, with particular emphasis on toxicological evaluation methodologies, quality control measures, and the critical importance of pharmacovigilance systems. Key themes explored include the scientific approaches to preclinical and clinical safety assessment, the pervasive challenges of ensuring product quality in the face of adulteration and environmental contamination, the heterogeneous regulatory frameworks that exist across major regions including the European Union, United States, China, and India, and the obstacles inherent in achieving standardization and evidence-based validation of herbal products. The article further examines post-market surveillance mechanisms and highlights persistent gaps in adverse event reporting systems specific to herbal medicines. Looking forward, the harmonization of international regulatory standards, implementation of digital pharmacovigilance platforms utilizing artificial intelligence and big data analytics, advancement of phytochemical fingerprinting technologies, and integration of herbal medicines into mainstream evidence-based medical practice represent crucial pathways toward optimizing safety profiles and ensuring that traditional knowledge is preserved while meeting contemporary scientific and regulatory expectations.

DOI:

Keywords: Herbal medicines, Safety, Toxicity, Regulatory frameworks, Quality control, Pharmacovigilance, Standardization, Evidence-based herbal therapy

Introduction

Herbal medicines, also referred to as botanical medicines, phytomedicines, or traditional herbal medicinal products, encompass a diverse array of plant-derived preparations used for therapeutic, preventive, or health-promoting purposes. These remedies have formed the cornerstone of traditional medical systems including Traditional Chinese Medicine, Ayurveda, Unani, and numerous indigenous healing practices worldwide [1]. The resurgence of interest in herbal medicines during recent decades can be attributed to multiple factors including growing concerns about adverse effects associated with synthetic pharmaceuticals, increasing healthcare costs, limited access to conventional medical services in resource-constrained settings, and a cultural shift toward natural and holistic approaches to health and wellness [2]. The global herbal medicine market has experienced exponential growth, with estimates suggesting it exceeded 150 billion United States dollars in valuation by 2023, and projections indicating continued expansion driven by consumer demand in both developed and developing nations [3]. Despite this widespread use and commercial success, a fundamental misconception persists among consumers and even some healthcare

practitioners that herbal medicines are inherently safe simply because they are natural products [4]. This perception stands in stark contrast to mounting scientific evidence documenting that herbal preparations can exhibit significant toxicity, cause serious adverse reactions, interact with conventional medications in clinically meaningful ways, and present quality-related hazards including contamination with toxic substances and intentional adulteration with undeclared synthetic drugs [5]. The complexity of herbal medicines, which typically contain multiple bioactive compounds with diverse pharmacological activities, presents unique challenges for safety assessment that differ fundamentally from those encountered with single-molecule synthetic drugs [6]. Furthermore, variations in plant species identification, geographical origin, cultivation practices, harvesting methods, processing techniques, and storage conditions can result in substantial inconsistencies in chemical composition and biological activity, thereby complicating efforts to ensure consistent safety and efficacy profiles [7].

The regulatory landscape governing herbal medicines exhibits remarkable heterogeneity across different countries and regions, ranging from stringent pharmaceutical-style regulations to minimal oversight, creating challenges for international trade, consumer protection, and public health initiatives [8]. In recognition of these concerns, regulatory authorities, international organizations, and the scientific community have increasingly focused attention on developing robust frameworks for toxicological evaluation, quality assurance, standardization, and post-market surveillance of herbal products [9]. This article provides a comprehensive examination of the current state of knowledge regarding safety and toxicity aspects of herbal medicines, critically evaluates existing regulatory approaches and quality control methodologies, discusses the role of pharmacovigilance in detecting and preventing adverse events, and proposes future directions for enhancing the safe and rational use of these therapeutically important yet complex natural products.

Overview of Herbal Medicines and Their Global Usage

The utilization of herbal medicines spans millennia and encompasses virtually every human culture and geographical region, with archaeological evidence suggesting that plant-based remedies were employed by prehistoric societies for treating ailments and maintaining health [10]. Contemporary global usage patterns reveal that herbal medicines occupy a prominent position in healthcare systems across both developing and industrialized nations, though the context, regulatory status, and integration with conventional medicine vary considerably. In many Asian, African, and Latin American countries, traditional herbal remedies represent the primary or sole source of healthcare for large segments of the population, particularly in rural and underserved communities where access to modern medical facilities and pharmaceuticals remains limited [11]. The World Health Organization has acknowledged the critical role of traditional medicine in achieving universal health coverage and has established strategic initiatives to promote the safe and effective integration of traditional and complementary medicine into national health systems [12].

In contrast, herbal medicines in Western industrialized nations are predominantly used as complementary or alternative therapies alongside conventional medical treatments, often for chronic conditions including arthritis, anxiety, depression, insomnia, and digestive disorders, as well as for general wellness and disease prevention purposes [13]. Epidemiological surveys conducted in Europe, North America, and Australia consistently indicate that between 20% and 70% of the general population have used herbal products at some point, with higher prevalence rates observed among individuals with chronic illnesses, higher educational attainment, and those actively seeking natural or holistic health approaches [14]. Commonly used herbal medicines in Western markets include Echinacea species for immune support and upper respiratory tract infections, St. John's wort for mild to moderate depression, ginkgo biloba for cognitive enhancement and circulatory disorders, valerian for sleep disturbances, and saw palmetto for benign prostatic hyperplasia [15].

The global herbal medicine market is characterized by diverse product categories including crude botanical materials, dried herbs, herbal teas, tinctures, fluid extracts, powdered extracts, standardized extracts, and various finished dosage forms such as tablets, capsules, and topical preparations [16]. Traditional herbal formulations often comprise multiple botanical ingredients combined according to principles established in traditional medical systems, whereas modern phytopharmaceuticals typically contain single herbs or isolated active constituents subjected to pharmaceutical quality standards [17]. The production and distribution chain for herbal medicines involves cultivators, wild harvesters, processors, manufacturers, distributors, and retailers, creating multiple points at which quality, safety, and authenticity can be compromised [18]. Consumer motivations for using herbal medicines include perceived natural safety, cultural or traditional beliefs, dissatisfaction with conventional medical treatments, desire for greater personal control over health decisions, and recommendations from family members, friends, or alternative health practitioners [19].

However, patterns of herbal medicine use also raise important public health concerns, as studies have documented that a substantial proportion of users do not disclose their herbal product consumption to healthcare providers, potentially leading to missed opportunities for identifying herb-drug interactions, contraindications, or inappropriate self-medication [20]. Additionally, the ease of access to herbal products through retail outlets, online platforms, and direct marketing channels occurs in the absence of prescription requirements or professional guidance in many jurisdictions, increasing the risk of misuse, incorrect dosing, and consumption of inappropriate or low-quality products [21]. The globalization of herbal medicine markets has facilitated international trade in botanical materials and finished products, creating opportunities for economic development but also introducing challenges related to species conservation, sustainable harvesting practices, equitable benefit sharing, and cross-border regulatory coordination [22].

Toxicological Evaluation and Safety Assessment

The toxicological evaluation of herbal medicines presents unique methodological and conceptual challenges that distinguish it from conventional pharmaceutical drug development and safety assessment paradigms [23]. Unlike single chemical entities with well-defined structures and properties, herbal preparations contain complex mixtures of dozens to hundreds of chemical constituents including alkaloids, glycosides, terpenes, phenolic compounds, and

volatile oils, many of which may contribute to biological activity through additive, synergistic, or antagonistic interactions [24]. This chemical complexity necessitates the development of specialized toxicological approaches that can adequately characterize the safety profile of the complete herbal preparation while also identifying specific constituents that may pose toxicological concerns [25]. Traditional toxicological paradigms developed for synthetic drugs, which focus on dose-response relationships for single molecules, must be adapted to accommodate the multicomponent nature of herbal medicines and the potential for constituent-specific or formulation-specific toxic effects [26].

Preclinical toxicological assessment of herbal medicines typically encompasses acute toxicity studies to determine the median lethal dose and identify target organs of toxicity, repeated-dose toxicity studies of varying durations to evaluate cumulative toxic effects and establish no-observed-adverse-effect levels, genotoxicity testing to assess mutagenic and clastogenic potential, reproductive and developmental toxicity studies to identify teratogenic or fertility-related risks, and carcinogenicity studies for products intended for long-term use [27]. However, the application of these standard toxicological testing protocols to herbal medicines is complicated by several factors including the lack of standardized test materials, variability in chemical composition between batches and sources, difficulties in achieving sufficiently high doses in animal models when testing crude botanical materials, and questions regarding the relevance of traditional toxicological endpoints to herbal products with long histories of human use [28]. Some regulatory frameworks have consequently adopted modified approaches that take into account traditional knowledge and documented patterns of safe use, allowing abbreviated toxicological data packages for herbal medicines with well-established traditional use, while requiring more comprehensive toxicological evaluation for novel herbal products or those without extensive usage history [29].

Specific toxicological concerns associated with herbal medicines include hepatotoxicity, which has been documented for numerous botanical species including kava, greater celandine, and various Chinese herbal formulations; nephrotoxicity associated with aristolochic acid-containing plants and certain traditional remedies; cardiovascular toxicity linked to ephedra-containing products and cardiac glycoside-bearing plants; and neurotoxicity associated with pyrrolizidine alkaloid-containing herbs [30]. Intrinsic toxicity may result from inherent chemical constituents of the plant material itself, while extrinsic toxicity can arise from contamination with pesticides, heavy metals, microbial toxins, or intentional adulteration with synthetic pharmaceutical substances [31]. The assessment of herb-drug interactions represents another critical dimension of safety evaluation, as numerous herbal medicines have been shown to modulate drug-metabolizing enzymes, particularly cytochrome P450 isoforms, and membrane transport proteins, potentially altering the pharmacokinetics and therapeutic or toxic effects of co-administered medications [32].

Clinical safety assessment of herbal medicines ideally includes well-designed randomized controlled trials that systematically collect and analyze adverse event data, though such rigorous studies remain relatively uncommon compared to the extensive clinical trial programs required for synthetic drug approval [33]. Clinical trials of herbal products should incorporate appropriate safety monitoring parameters including clinical chemistry, hematology, vital signs, and systematic solicitation of adverse events using validated instruments [34]. Long-term observational studies and post-marketing surveillance provide valuable complementary information on safety profiles in real-world usage conditions and diverse patient populations [35]. Special consideration must be given to vulnerable populations including pregnant and lactating women, children, elderly individuals, and those with hepatic or renal impairment, as safety data in these groups are often limited or entirely absent [36]. The establishment of appropriate reference standards, validated analytical methods, and quality control procedures represents a prerequisite for meaningful toxicological evaluation, ensuring that the test material accurately represents the product to be marketed and used clinically [37].

Quality Control, Adulteration, and Contamination Risks

Quality control of herbal medicines encompasses a comprehensive set of procedures and analytical methods designed to ensure the identity, purity, content, and consistency of botanical materials and finished products, thereby serving as a critical determinant of both safety and efficacy [38]. Unlike synthetic pharmaceuticals produced through controlled chemical synthesis with predictable and reproducible outcomes, herbal medicines are subject to extensive natural variation influenced by genetic factors, environmental conditions, agricultural practices, developmental stage at harvest, and post-harvest processing and storage conditions [39]. Consequently, robust quality control systems must address multiple potential sources of variation and contamination throughout the production chain from cultivation or wild collection through manufacturing and distribution to the end consumer [40]. Authentication of botanical identity represents a fundamental quality control measure, as misidentification or substitution of plant species can result in products lacking therapeutic activity or, more seriously, containing toxic constituents from incorrectly identified species [41].

Traditional methods of botanical identification including macroscopic and microscopic morphological examination require specialized expertise and may be inadequate for processed materials, powders, or extracts where diagnostic features have been altered or destroyed [42]. Modern authentication approaches increasingly employ chemical fingerprinting techniques using high-performance liquid chromatography, gas chromatography-mass spectrometry, or nuclear magnetic resonance spectroscopy to establish characteristic chemical profiles that can serve as species-specific markers [43]. DNA-based methods including DNA barcoding and quantitative polymerase chain reaction offer powerful tools for botanical authentication with high specificity and sensitivity, particularly valuable for identifying materials in highly processed forms or detecting undeclared plant species in complex formulations. Quantitative determination of marker compounds or groups of active constituents provides essential information for ensuring consistent potency and enabling appropriate dosing, with specifications typically established based on the content of pharmacologically active or characteristic phytochemicals. Contamination of herbal medicines with heavy metals including lead, cadmium, arsenic, and mercury poses significant health risks, particularly for products intended for

long-term use or consumed by vulnerable populations. Heavy metal contamination can occur through uptake from contaminated soils during cultivation, absorption of atmospheric pollutants, or intentional addition in certain traditional medicine systems where specific minerals are incorporated as therapeutic ingredients. Pesticide residues represent another major contamination concern, as agricultural production of medicinal plants may involve application of insecticides, herbicides, fungicides, and fumigants, residues of which can persist in harvested materials if good agricultural practices are not followed. Microbiological contamination with pathogenic bacteria, molds, or their toxic metabolites including aflatoxins poses risks of acute infection or toxicity, necessitating establishment of appropriate microbial limits and implementation of sanitary processing conditions.

Adulteration of herbal medicines, defined as the intentional addition of undeclared substances or substitution with inferior or fraudulent materials, represents a pervasive problem with serious safety implications. Economic adulteration, motivated by profit maximization, may involve dilution with inert materials, substitution of expensive botanical ingredients with cheaper alternatives, or artificial enhancement of marker compound levels through addition of isolated chemicals. More dangerous is the surreptitious addition of synthetic pharmaceutical drugs to herbal products marketed for conditions such as sexual dysfunction, weight loss, diabetes management, or pain relief, with numerous documented cases of products containing undeclared sildenafil, sibutramine, glibenclamide, or non-steroidal anti-inflammatory drugs at potentially harmful concentrations. Detection of such adulteration requires sophisticated analytical methods and surveillance programs, as the presence of synthetic drugs is not suspected based on labeled ingredients and traditional screening approaches may fail to identify these adulterants.

Quality control challenges are further amplified in the context of traditional multi-ingredient herbal formulations where complex interactions between constituents may influence stability, bioavailability, and therapeutic activity in ways that are difficult to predict or monitor using conventional analytical approaches. Good manufacturing practices specifically adapted for herbal medicines provide systematic frameworks for ensuring consistent quality, encompassing requirements for facility design, equipment qualification, personnel training, standard operating procedures, documentation systems, and quality assurance programs. However, implementation of such practices remains incomplete across the global herbal medicine industry, particularly among small-scale producers in developing countries where resources and technical capacity may be limited. International efforts to develop harmonized quality standards, analytical methods, and good practice guidelines, including initiatives by the World Health Organization, International Organization for Standardization, and pharmacopoeial authorities, represent important steps toward improving quality control on a global scale.

Regulatory Frameworks for Herbal Products Across Major Regions

The regulatory approaches applied to herbal medicines vary dramatically across different countries and regions, reflecting diverse historical, cultural, economic, and political factors that shape national health policies and pharmaceutical regulatory systems. This heterogeneity in regulatory frameworks creates challenges for international trade, mutual recognition of approval decisions, harmonization of quality standards, and coordination of safety surveillance efforts. Major regulatory paradigms can be broadly categorized into several models including regulation as conventional pharmaceuticals requiring full demonstration of quality, safety, and efficacy through standard drug development pathways; regulation as traditional herbal medicinal products with simplified registration procedures based on traditional use documentation; regulation as dietary supplements or food products subject to less stringent premarket requirements; and minimal or absent regulatory oversight allowing free market access.

In the European Union, the Traditional Herbal Medicinal Products Directive established in 2004 created a simplified registration pathway for herbal medicines with documented traditional use of at least 30 years, including 15 years within the EU, permitting marketing authorization without the need for clinical efficacy data but requiring demonstration of pharmaceutical quality and safety. This framework recognizes the distinct characteristics of traditional herbal medicines while ensuring a minimum level of quality assurance and safety evaluation. Products qualifying for traditional use registration must be administered according to specified strength and posology, intended for minor health complaints amenable to self-medication, and manufactured in accordance with good manufacturing practice standards. Herbal products making therapeutic claims that cannot be supported by traditional use documentation, including those with less than 30 years of use or intended for serious medical conditions, must undergo the standard marketing authorization procedure applicable to conventional pharmaceuticals with full preclinical and clinical evidence of efficacy and safety.

In the United States, most herbal products are regulated as dietary supplements under the Dietary Supplement Health and Education Act of 1994, which created a distinct regulatory category separate from conventional drugs and food additives. Under this framework, manufacturers are responsible for ensuring the safety of their products before marketing, but premarket approval by the Food and Drug Administration is not required, and efficacy claims are limited to structure-function statements that do not imply treatment or prevention of disease. The FDA may take enforcement action against unsafe or misbranded dietary supplements through post-market surveillance and adverse event monitoring, but the burden of demonstrating harm rests with the agency rather than manufacturers being required to prove safety before marketing. Current good manufacturing practice regulations specific to dietary supplements establish minimum standards for production, quality control, and documentation, though these requirements are generally less stringent than those applied to pharmaceutical drugs.

Traditional Chinese Medicine and herbal products in China are regulated under a comprehensive framework overseen by the National Medical Products Administration, which maintains separate regulatory pathways for traditional Chinese medicine preparations, including classical formulations, hospital preparations, and new traditional Chinese medicine drugs. Traditional formulations with long historical use may be approved based on classical literature references and traditional theory without modern clinical trials, whereas new traditional Chinese medicine products

require varying levels of preclinical and clinical data depending on novelty and intended indications. China has invested substantial resources in modernizing traditional Chinese medicine manufacturing through implementation of good manufacturing practices, development of quality standards, and establishment of adverse reaction monitoring systems.

India's regulatory framework for Ayurvedic, Siddha, and Unani medicines falls under the purview of the Ministry of AYUSH, with separate provisions from conventional pharmaceuticals recognizing the distinct philosophical and practical foundations of traditional Indian medicine systems. Classical Ayurvedic formulations documented in authorized texts may be manufactured and marketed without clinical trial data, while new formulations require safety and efficacy evaluation. However, implementation and enforcement of quality standards and good manufacturing practices remain inconsistent, with significant variation in the quality and safety of products in the marketplace. Other countries employ diverse regulatory approaches ranging from the highly stringent systems of Canada and Australia, which require substantial evidence of safety and quality with traditional use or limited efficacy data, to minimal oversight in many developing countries where herbal products may be marketed with little or no regulatory review.

International harmonization efforts including the World Health Organization guidelines on herbal medicines, International Conference on Harmonisation initiatives, and regional collaborative platforms seek to promote convergence toward common quality standards, safety assessment approaches, and information exchange mechanisms. However, achieving meaningful harmonization is complicated by fundamental philosophical differences regarding the evidentiary basis for approval, cultural attitudes toward traditional medicine, economic considerations related to domestic herbal medicine industries, and practical challenges in establishing equivalent standards for botanically diverse products.

Pharmacovigilance and Post-Market Surveillance

Pharmacovigilance, defined as the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other medicine-related problems, plays a critical role in ensuring the ongoing safety of herbal medicines throughout their marketed life. While premarket safety evaluation through toxicological studies and clinical trials can identify common and predictable adverse effects, post-market surveillance is essential for detecting rare adverse events, long-term toxicities, effects in special populations, herb-drug interactions manifesting in clinical practice, and safety issues arising from poor quality, adulteration, or misuse. The importance of pharmacovigilance for herbal medicines is underscored by numerous examples of serious adverse effects that were not recognized until years after products entered widespread use, including the nephrotoxicity and urothelial carcinomas associated with aristolochic acid-containing herbs, and the hepatotoxicity linked to kava preparations.

Spontaneous adverse event reporting systems, whereby healthcare professionals, patients, and manufacturers submit reports of suspected adverse reactions to regulatory authorities, represent the cornerstone of pharmacovigilance for herbal medicines as for conventional drugs. However, several factors limit the effectiveness of spontaneous reporting for herbal products including underreporting due to the perception that herbal medicines are safe and adverse events are rare or non-existent, lack of awareness among healthcare providers regarding the importance of reporting herbal medicine-related adverse events, difficulty in establishing causal relationships when patients are taking multiple medications and herbal products concurrently, and incomplete or inaccurate identification of the specific herbal product implicated due to poor quality of product information or complex multi-ingredient formulations.

Establishing causality between herbal medicine exposure and suspected adverse events presents particular challenges given the complex chemical composition of botanical products, individual variation in metabolism and susceptibility, potential for contamination or adulteration, and limited understanding of mechanisms of toxicity for many herbs. Causality assessment algorithms such as the Naranjo scale or WHO-UMC system can provide structured approaches to evaluating the likelihood that an adverse event was caused by a specific medicine, considering factors such as temporal relationship, dechallenge and rechallenge outcomes, alternative explanations, and consistency with known adverse effect profiles. However, these tools were developed primarily for conventional pharmaceuticals and may not adequately account for the unique characteristics of herbal medicines including delayed onset of effects, dose-independent idiosyncratic reactions, and variable product quality.

Signal detection, the process of identifying new or changing adverse event patterns that may represent previously unrecognized safety concerns, requires systematic analysis of pharmacovigilance databases using statistical methods and clinical judgment. For herbal medicines, signal detection is complicated by inconsistent nomenclature and identification of botanical products in adverse event reports, with the same plant potentially being referred to by multiple common names, scientific names, or traditional designations, and conversely, the same common name sometimes applied to different botanical species. Data mining techniques and natural language processing algorithms are increasingly being applied to identify potential signals in large pharmacovigilance databases, though their application to herbal medicines remains in relatively early stages compared to conventional drugs.

Several countries have established specialized pharmacovigilance programs focused specifically on herbal and traditional medicines, including the WHO Programme for International Drug Monitoring which has developed specific coding and reporting formats for traditional medicines, and national initiatives such as the Australian Adverse Medicine Events Line and the United States FDA MedWatch system which accept reports on dietary supplements and herbal products. However, global coverage and utilization of these systems remain suboptimal, with substantial underreporting particularly in regions where herbal medicine use is most prevalent. Active surveillance methods including cohort studies, case-control studies, prescription event monitoring, and electronic health record data mining offer complementary approaches to spontaneous reporting, providing denominator data on exposed populations and enabling calculation of absolute risk and incidence rates rather than relying solely on

disproportionality analyses.

The integration of pharmacovigilance data with quality surveillance programs that monitor for contamination, adulteration, and substandard products represents an important strategy for distinguishing safety issues arising from the herbal medicine itself versus those resulting from quality defects. Risk management and risk communication following identification of safety signals must balance protection of public health with avoiding unnecessary alarm or restriction of access to beneficial herbal medicines, requiring careful evaluation of the strength of evidence, severity and frequency of adverse effects, availability of safer alternatives, and feasibility of risk minimization measures such as contraindications, warnings, dosing restrictions, or formulation changes.

Challenges in Standardization and Evidence-Based Evaluation

Standardization of herbal medicines encompasses multiple dimensions including botanical standardization to ensure correct species identification and consistent source materials, chemical standardization to establish reproducible content of active or marker compounds, and biological or pharmacological standardization to confirm consistent therapeutic activity. Achieving meaningful standardization is complicated by the inherent variability of plant materials, the multicomponent nature of herbal preparations, and ongoing scientific uncertainty regarding which constituents are responsible for therapeutic effects in many traditional herbal medicines. The concept of standardization itself may be at odds with certain traditional medicine philosophies that emphasize holistic activity of crude preparations and view attempts to isolate or quantify specific compounds as reductionist and inconsistent with traditional principles.

Chemical standardization typically involves establishing specifications for the content of one or more marker compounds, which may be pharmacologically active constituents with demonstrated therapeutic activity, characteristic compounds that serve as markers for species identification and quality assessment even if their pharmacological contribution is unclear, or analytical markers selected primarily for ease of quantification and stability. Standardized extracts manufactured to contain specified concentrations of marker compounds offer advantages of improved dose consistency and reproducibility compared to crude botanical materials, facilitating evidence-based evaluation and rational clinical use. However, standardization based solely on marker compound content does not guarantee equivalent therapeutic activity if other constituents contributing to activity are not similarly controlled, or if processing methods alter the chemical profile or bioavailability of active compounds.

The evidence base supporting the efficacy and safety of herbal medicines remains incomplete and inconsistent in quality, with substantial variation in the rigor of clinical research across different products and indications. While a growing number of herbal medicines have been subjected to randomized controlled trials, systematic reviews, and meta-analyses, the overall quality of clinical trial evidence is often limited by methodological deficiencies including small sample sizes, inadequate randomization or blinding procedures, poorly defined interventions using unstandardized herbal products, inappropriate comparator selection, short treatment durations, and inadequate safety monitoring. The lack of product standardization in many clinical trials further compromises the ability to draw definitive conclusions about efficacy and safety, as positive or negative findings may reflect the specific product tested rather than the herbal medicine in general.

Translating traditional knowledge and historical patterns of use into evidence acceptable under modern regulatory and clinical paradigms presents conceptual and practical challenges, as traditional systems of medicine employ different frameworks for understanding disease causation, diagnosis, and treatment compared to biomedical models. Traditional herbal formulations are often prescribed in individualized combinations tailored to specific patient presentations according to traditional diagnostic principles, an approach that conflicts with the standardized interventions and population-based outcome measures employed in conventional clinical trials. Some scholars have advocated for alternative research methodologies better suited to evaluating traditional medicine practices including whole systems research, pragmatic trials, comparative effectiveness research, and outcomes-based approaches that accommodate individualized treatment while maintaining scientific rigor.

The integration of herbal medicines into evidence-based clinical practice guidelines and mainstream healthcare systems requires overcoming barriers including limited high-quality clinical evidence, lack of standardized prescribing information and dosing recommendations, inadequate education of healthcare professionals regarding appropriate indications and contraindications, concerns about herb-drug interactions and safety in vulnerable populations, and philosophical or cultural resistance from both conventional medical practitioners and traditional medicine advocates. Successful integration models such as those implemented in some European and Asian countries typically involve development of national treatment guidelines based on systematic evidence review, establishment of professional training and certification standards for herbal medicine practitioners, implementation of quality assurance and regulatory oversight systems, and promotion of collaborative practice between conventional and traditional medicine providers.

Future Directions: Harmonization, Digital Monitoring, and Safety Optimization

The future trajectory of herbal medicine safety and regulation will likely be shaped by several key trends including increased international harmonization of regulatory standards and safety monitoring systems, application of advanced analytical technologies for quality control and authentication, implementation of digital pharmacovigilance platforms leveraging big data and artificial intelligence, and continued evolution of evidence standards balancing traditional knowledge with contemporary scientific methodologies. International harmonization efforts must address not only technical aspects of quality standards and safety assessment protocols but also fundamental questions regarding the appropriate regulatory classification of herbal medicines and the evidentiary basis for marketing authorization. Regional harmonization initiatives such as those undertaken by the Association of Southeast Asian Nations and the East African Community may provide valuable models for achieving regulatory convergence while respecting national sovereignty and cultural diversity. Advanced analytical technologies including metabolomics, proteomics, and multi-

omics approaches offer powerful tools for comprehensive chemical characterization of herbal medicines, identification of quality markers and bioactive constituents, elucidation of mechanisms of action, and detection of adulteration or contamination. High-resolution mass spectrometry coupled with chemometric analysis enables generation of detailed chemical fingerprints that can serve as unique identifiers for botanical species and detect even minor variations in composition. Isotope ratio mass spectrometry and stable isotope analysis provide means of determining geographical origin and authenticity of botanical materials, supporting traceability throughout the supply chain and combating fraudulent practices. DNA metabarcoding allows simultaneous identification of multiple plant species in complex mixtures, facilitating quality control of multi-ingredient formulations and detection of undeclared ingredients or substitutions.

Digital pharmacovigilance represents a transformative approach to safety monitoring that harnesses electronic health records, social media, online consumer reviews, and mobile health applications to detect adverse event signals in real-time from diverse data sources. Natural language processing and machine learning algorithms can automatically extract adverse event information from unstructured text data, identify temporal patterns suggestive of safety concerns, and generate alerts for further investigation. Blockchain technology offers potential applications in ensuring traceability and authenticity of herbal products throughout the supply chain, creating immutable records of origin, processing steps, quality testing results, and distribution pathways that can enhance consumer confidence and regulatory oversight. Artificial intelligence and predictive toxicology models can facilitate safety assessment by predicting potential toxicities of herbal constituents based on chemical structure, reducing reliance on animal testing, and prioritizing compounds for further evaluation.

The concept of precision herbal medicine, which applies pharmacogenomic and metabolomic principles to optimize herbal treatment selection and dosing based on individual patient characteristics, represents an emerging frontier that could enhance both efficacy and safety by accounting for genetic variation in drug metabolism, disease susceptibility, and therapeutic response. Systems pharmacology approaches that model the complex interactions between multiple herbal constituents and biological targets may provide deeper understanding of mechanisms of action and potential adverse effects, supporting more rational use and combination of herbal medicines. Sustainable cultivation and wild harvesting practices, standardized good agricultural and collection practices, and conservation strategies for medicinal plant species represent critical priorities for ensuring long-term availability of high-quality botanical materials while protecting biodiversity and supporting local communities.

Education and training initiatives targeting healthcare professionals, traditional medicine practitioners, regulatory officials, quality control personnel, and consumers represent essential investments in building capacity for safe and effective use of herbal medicines. Interdisciplinary collaboration among botanists, pharmacologists, toxicologists, chemists, clinicians, traditional medicine practitioners, regulatory scientists, and public health professionals is necessary to address the multifaceted challenges surrounding herbal medicine safety and to develop holistic solutions that honor traditional knowledge while meeting contemporary scientific and regulatory standards. Continued research investment in herbal medicine safety, efficacy, and quality is needed to fill knowledge gaps, validate traditional uses through rigorous scientific methods, develop improved standardization approaches, and support evidence-based integration of valuable herbal therapies into mainstream healthcare systems.

Conclusion

Herbal medicines represent a therapeutically significant and culturally important component of global healthcare that warrants serious attention to safety, quality, and regulatory oversight commensurate with their widespread use and potential risks. While the natural origin of herbal products contributes to their appeal and perceived safety, scientific evidence clearly demonstrates that botanical medicines can exhibit significant toxicity, interact with conventional drugs, and pose quality-related hazards including contamination and adulteration. Comprehensive toxicological evaluation using both traditional testing paradigms and innovative approaches adapted to the unique characteristics of complex botanical mixtures is essential for characterizing safety profiles and establishing appropriate use conditions. Robust quality control systems encompassing botanical authentication, chemical standardization, contamination testing, and good manufacturing practices represent fundamental prerequisites for ensuring that herbal products meet acceptable standards of identity, purity, and consistency.

The heterogeneous regulatory frameworks governing herbal medicines across different countries reflect diverse cultural and philosophical perspectives but create challenges for international trade, harmonization of standards, and optimal protection of public health. Strengthening pharmacovigilance systems specifically designed for herbal medicines, improving adverse event reporting and signal detection, and integrating safety surveillance with quality monitoring are critical for early identification and management of emerging safety concerns. Challenges in achieving meaningful standardization and generating high-quality clinical evidence require innovative approaches that balance respect for traditional knowledge with rigorous scientific evaluation, supporting evidence-based integration of herbal medicines into mainstream healthcare practice. Looking forward, international collaboration in regulatory harmonization, application of advanced analytical and digital technologies, implementation of sophisticated pharmacovigilance platforms, and continued research investment in safety, efficacy, and quality offer promising pathways toward optimizing the safe use of herbal medicines while preserving the rich heritage of traditional healing knowledge for future generations.

Figures

Fig 1: Common safety concerns and toxicological risks associated with herbal medicines.



Fig 2: Workflow for preclinical and clinical toxicological assessment of herbal products.



Fig 3: Global regulatory frameworks for herbal medicines, highlighting differences across regions.



Fig 4: Integrated approach to herbal medicine safety, quality control, and pharmacovigilance.

References

1. World Health Organization. WHO traditional medicine strategy: 2014-2023. Geneva: World Health Organization; 2013.
2. Ekor M. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Front Pharmacol. 2014;4:177.
3. Smith T, Gillespie M, Eckl V, Knepper J, Reynolds CM. Herbal supplement sales in US increase by 9.7% in 2021. HerbalGram. 2022;135:56-73.
4. Posadzki P, Watson L, Ernst E. Contamination and adulteration of herbal medicinal products: an overview of systematic reviews. Eur J Clin Pharmacol. 2013;69(3):295-307.
5. Teschke R, Wolff A, Frenzel C, Schulze J. Herbal hepatotoxicity - an update on traditional Chinese medicine preparations. Aliment Pharmacol Ther. 2014;40(1):32-50.
6. Heinrich M, Appendino G, Efferth T, Fürst R, Izzo AA, Kayser O, *et al*. Best practice in research - overcoming common challenges in phytopharmacological research. J Ethnopharmacol. 2020;246:112230.
7. Booker A, Jalil B, Frommenwiler D, Reich E, Zhai L, Kulic Z, *et al*. The authenticity and quality of Rhodiola rosea products. Phytomedicine. 2016;23(7):754-762.
8. Wiesner J, Knöss W. Future visions for traditional and herbal medicinal products - a global practice for evaluation and regulation. J Ethnopharmacol. 2014;158(Pt B):516-518.
9. Shaw D, Graeme L, Pierre D, Elizabeth W, Kelvin C. Pharmacovigilance of herbal medicine. J Ethnopharmacol. 2012;140(3):513-518.
10. Petrovska BB. Historical review of medicinal plants usage. Pharmacogn Rev. 2012;6(11):1-5.
11. Tilburt JC, Kaptchuk TJ. Herbal medicine research and global health: an ethical analysis. Bull World Health Organ. 2008;86(8):594-599.
12. Robinson MM, Zhang X. The world medicines situation 2011: traditional medicines: global situation, issues and challenges. Geneva: World Health Organization; 2011.
13. Clarke TC, Black LI, Stussman BJ, Barnes PM, Nahin RL. Trends in the use of complementary health approaches among adults: United States, 2002-2012. Natl Health Stat Report. 2015;(79):1-16.
14. Harris PE, Cooper KL, Relton C, Thomas KJ. Prevalence of complementary and alternative medicine use by the general population: a systematic review of the literature. Complement Ther Med. 2012;20(4):246-255.
15. Bent S. Herbal medicine in the United States: review of efficacy, safety, and regulation. J Gen Intern Med. 2008;23(6):854-859.
16. Braun L, Cohen M. Herbs and natural supplements: an evidence-based guide. 4th ed. Sydney: Churchill Livingstone; 2015.
17. Mukherjee PK, Harwansh RK, Bahadur S, Banerjee S, Kar A, Chanda J, *et al*. Development of Ayurveda - tradition to trend. J Ethnopharmacol. 2017;197:10-24.
18. Booker A, Frommenwiler D, Reich E, Horsfield S, Heinrich M. Adulteration and poor quality of Ginkgo biloba supplements. J Herb Med. 2016;6(2):79-87.
19. Tangkiatkumjai M, Boardman H, Walker DM. Potential factors that influence usage of complementary and alternative medicine worldwide: a systematic review. BMC Complement Med Ther. 2020;20(1):363.
20. Jou J, Johnson PJ. Nondisclosure of complementary and alternative medicine use to primary care physicians: findings from the 2012 National Health Interview Survey. JAMA Intern Med. 2016;176(4):545-546.
21. Newmaster SG, Grguric M, Shanmughanandhan D, Ramalingam S, Ragupathy S. DNA barcoding detects contamination and substitution in North American herbal products. BMC Med. 2013;11:222.
22. Schippmann U, Leaman DJ, Cunningham AB. Impact of cultivation and gathering of medicinal plants on biodiversity: global trends and issues. Biodivers Agric. 2002;1-21.
23. Pelkonen O, Xu Q, Fan TP. Why is research on herbal medicinal products important and how can we improve its quality. J Tradit Complement Med. 2014;4(1):1-7.
24. Wiesner J, Knöss W. Future visions for traditional and herbal medicinal products - a global practice for evaluation and regulation. J Ethnopharmacol. 2014;158(Pt B):516-518.
25. Zhou SF, Xue CC, Yu XQ, Li C, Wang G. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit. 2007;29(6):687-710.
26. Brinker F. Herb contraindications and drug interactions. 4th ed. Sandy, OR: Eclectic Medical Publications; 2010.
27. Organisation for Economic Co-operation and Development. OECD guidelines for the testing of chemicals. Paris: OECD Publishing; 2018.
28. World Health Organization. WHO guidelines for assessing quality of herbal medicines with reference to

contaminants and residues. Geneva: World Health Organization; 2007.
29. European Medicines Agency. Guideline on the assessment of genotoxicity of herbal substances/preparations. London: EMA; 2008.
30. Stickel F, Shouval D. Hepatotoxicity of herbal and dietary supplements: an update. Arch Toxicol. 2015;89(6):851-865.
31. Raynor DK, Dickinson R, Knapp P, Long AF, Nicolson DJ. Buyer beware? Does the information provided with herbal products available over the counter enable safe use. BMC Med. 2011;9:94.
32. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs. 2009;69(13):1777-1798.
33. Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C. Recommendations for reporting randomized controlled trials of herbal interventions: explanation and elaboration. J Clin Epidemiol. 2006;59(11):1134-1149.
34. Ioannidis JP, Evans SJ, Gøtzsche PC, O'Neill RT, Altman DG, Schulz K, *et al*. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med. 2004;141(10):781-788.
35. Mann RD, Andrews EB. Pharmacovigilance. 2nd ed. Chichester: John Wiley & Sons; 2007.
36. Ernst E. Herbal medicinal products during pregnancy: are they safe. BJOG. 2002;109(3):227-235.
37. World Health Organization. Quality control methods for herbal materials. Geneva: World Health Organization; 2011.
38. Lahlou M. The success of natural products in drug discovery. Pharmacol Pharm. 2013;4:17-31.
39. Jaafar NS, Hamad MN, Alshammaa DA, Abd AN. Review on heavy metal toxicity and herbal medicine. Arch Razi Inst. 2021;76(4):859-872.
40. Zhao Z, Guo P, Brand E. The formation of daodi medicinal materials. J Ethnopharmacol. 2012;140(3):476-481.
41. Palhares RM, Drummond MG, Brasil BS, Cosenza GP, Brandão MG, Oliveira G. Medicinal plants recommended by the world health organization: DNA barcode identification associated with chemical analyses guarantees their quality. PLoS One. 2015;10(5):e0127866.
42. Kellogg JJ, Todd DA, Egan JM, Raja HA, Oberlies NH, Kvalheim OM, *et al*. Biochemometrics for natural products research: comparison of data analysis approaches and application to identification of bioactive compounds. J Nat Prod. 2016;79(2):376-386.
43. Wolfender JL, Marti G, Thomas A, Bertrand S. Current approaches and challenges for the metabolite profiling of complex natural extracts. J Chromatogr A. 2015;1382:136-164.